The analyst rating for XTALPI (02228.HK) is a "Buy" based on several key factors highlighted in the Cinda Securities research report. The company is recognized as a leader in the cutting-edge technology segment, particularly in robotics and AI pharmaceuticals, which reflects its dual innovation concepts. From a medium-to-long-term perspective, XTALPI's advanced industrial model is expected to drive technological advancements in the industry, providing significant growth potential. Cinda Securities forecasts substantial increases in operating revenue over the next few years, with projected revenues of RMB781 million, RMB1.093 billion, and RMB1.496 billion for 2025-2027, representing year-on-year growth of 193%, 40%, and 37%, respectively. Additionally, the forecast includes a turnaround in net profits, moving from losses to a profit of RMB100 million by 2027. These factors collectively support the positive rating.
